Sep 27 |
Cassava settles SEC charges related to Alzheimer’s candidate for $40M
|
Sep 27 |
Update: Cassava Sciences Pays $40 Million to Settle SEC Charges; Shares Drop Pre-Bell
|
Sep 26 |
Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
|
Sep 26 |
Cassava Sciences Resolves SEC Investigation
|
Sep 26 |
Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims
|
Sep 25 |
Cassava's Simufilam: Safe On The Outside, Scrambled On The Inside
|
Sep 25 |
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
|
Sep 25 |
Why I'm Avoiding Cassava Stock For Now
|
Sep 24 |
Cassava Sciences' on-going late stage trials for Alzheimer's treatment gets DSMB nod
|
Sep 24 |
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
|